Pradžia › Neurofibrosarkoma › New York
Neurofibrosarkoma klinikiniai tyrimai New York
6 tyrimai dėl Neurofibrosarkoma ieško dalyvių vietose New York.
Miestai New York
Oficialus tyrimo tekstas (anglų kalba)
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- New York University Langone Health, New York
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT05732831Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Perlmutter Cancer Center at NYU Langone Hospital Long Island, Mineola
- David H Koch, Memorial Sloan Kettering Cancer Center, New York
- New york cancer and blood specialists - Oncology, Port Jefferson Station
- ir dar 1
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT05245500SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
Renkami dalyviai1/2 fazė
Amžius nuo 2 iki 21 · Visoms lytims · Atnaujinta 2026-08-11 · NCT05642455A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
- ir dar 1
Renkami dalyviai2 fazė
12 Months · Visoms lytims · Atnaujinta 2026-05-06 · NCT05985161Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Memorial Sloan Kettering Cancer Center, New York
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-03-09 · NCT03141021A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- ir dar 1
Renkami dalyviai2 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-02-05 · NCT04872543Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.